SCNX
HEALTHCAREScienture Holdings Inc
Live · NASDAQ · May 9, Close
What's Moving SCNX Today?
No stock-specific AI insight has been generated for SCNX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.39
Fundamentals
Trading
SCNX News
20 articles- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D PipelineYahoo Finance·May 7, 2026
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041Yahoo Finance·May 6, 2026
- Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementYahoo Finance·Apr 15, 2026
- Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year AheadYahoo Finance·Apr 6, 2026
- SCIENTURE Reports Year End 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 30, 2026
- BC-Most Active StocksYahoo Finance·Mar 11, 2026
- SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. InstitutionsYahoo Finance·Mar 11, 2026
- SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan PotassiumYahoo Finance·Feb 3, 2026
- SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency TreatmentYahoo Finance·Jan 14, 2026
- SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDAYahoo Finance·Dec 22, 2025
- Scienture, BlinkRx announce strategic collaboration to expand access to ArbliYahoo Finance·Dec 11, 2025
- SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan PotassiumYahoo Finance·Dec 10, 2025
- Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025Yahoo Finance·Dec 8, 2025
- SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025Yahoo Finance·Dec 2, 2025
- iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025Yahoo Finance·Dec 1, 2025
- SCIENTURE Reports Q3 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 13, 2025
- EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt ReductionYahoo Finance·Nov 13, 2025
- Scienture Holdings: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health PlansYahoo Finance·Nov 4, 2025
- EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million LivesYahoo Finance·Nov 4, 2025
All 20 articles loaded
Price Data
52-Week Range
$0.39
Fundamentals
Trading
About Scienture Holdings Inc
Scienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to advancing therapeutic solutions for neurological disorders through its innovative drug development pipeline. Leveraging cutting-edge technology and a highly proficient research team, Scienture aims to address significant unmet medical needs while enhancing patient outcomes. The company's unwavering commitment to scientific excellence, regulatory adherence, and strategic partnerships not only fuels its growth prospects but also underscores its potential to deliver impactful contributions to global healthcare advancements. As the healthcare sector continues to expand, SCNX is well-positioned to capitalize on emerging opportunities in the neurological treatment landscape.